Patricia Allen
Director/Board Member presso DECIPHERA PHARMACEUTICALS, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Patricia L.
Allen is currently a Director at Deciphera Pharmaceuticals LLC, Anokion SA, Kanyos Bio, Inc., Inversago Pharma, Inc., SwanBio Therapeutics, Inc., and Chief Financial Officer at Vividion Therapeutics, Inc. She previously worked as a Finance Director at Alkermes, Inc., Audit Manager at Deloitte & Touche LLP, Chief Financial Officer, Treasurer & VP at Alnylam Pharmaceuticals, Inc., CFO, Treasurer & Principal Accounting Officer at Zafgen, Inc., and Director at Yumanity, Inc. and Yumanity Therapeutics, Inc. She received her undergraduate degree from Bryant University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
16/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Patricia Allen
Società | Posizione | Inizio |
---|---|---|
DECIPHERA PHARMACEUTICALS, INC. | Director/Board Member | 01/09/2016 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Director/Board Member | - |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Director/Board Member | - |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Director/Board Member | 29/09/2020 |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Director/Board Member | 20/11/2020 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Director of Finance/CFO | 01/03/2021 |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Precedenti posizioni note di Patricia Allen
Società | Posizione | Fine |
---|---|---|
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Director/Board Member | 22/12/2020 |
LARIMAR THERAPEUTICS, INC. | Director of Finance/CFO | 01/05/2020 |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formazione di Patricia Allen
Bryant University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
DECIPHERA PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 11 |
---|---|
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Health Technology |
Zafgen, Inc.
Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Health Services |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Health Technology |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Health Technology |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
Yumanity Therapeutics, Inc.
Yumanity Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Patricia Allen